Patent US4394249A successfully refreshed from Google Patents.
Patent EP0507484A1 successfully refreshed from Google Patents.
EP0507484A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A pharmaceutical formulation of aureobasidins
Assignee: Takara Shuzo Co Ltd
•
Filing: 1992-03-23
•
Granted: —
•
Expires: 2012-03-23
Abstract
Abstract There is provides a solid formulation of Aureobasidin suitable for clinical use. The solid formation of Aureobasidin contains at least one Aureobasidin and a surface-active agent. As the Aureobasidins, Aureobasidin A, its related compounds, or its derivatives can be used. As the surface-active agent, a nonionic kind is preferable. Other usual additives may be included. Oral administration of the formulation of this invention results in a concentration of the Aureobasidin in the blood high enough to give pharmaceutical effect such as antifungal activity.
Inventors
- 👤 Kazutoh Takesako
- 👤 Yoshie Yoshikawa
- 👤 Hiroyuki Kuroda
- 👤 Ikunoshin Kato
- 👤 Kazuhiro Inouye
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 20:20
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/15; A61K47/00; A61K47/44; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1617; A61P; A61P31/00; A61P31/04; A61P31/10
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
114 words
A pharmaceutical composition in solid form comprising a pharmacologically effective amount of Aureobasidin represented by the general formula [I]; in which: R is methyl or ethyl; A 1 is Phe, o-FPhe, m-FPhe, or Tyr; A 2 is MePhe, β-HOMePhe, Phe, o-FMePhe, m-FMePhe, MeTyr, Sar, MeSer, β-oxoMePhe, or β-R 2 OMePhe (wherein R 2 is a lower acyl group having 1 to 4 carbon atoms); A 3 is Pro, 4Hyp, or SPro; A 4 is allo-Ile, Val, Leu, or Nle; A 5 is MeVal or Val; A 6 is Leu or Nva; and A 7 is β-HOMeVal, γ-HOMeVal, MeVal, N,β-MeAsp, β-HOMePhe, MePhe, MeDH 2,3 Val, MeDH 3,4 Val, or Sar, and a nontoxic surface-active agent.
Claim 2
Dependent Claim
16 words
A pharmaceutical composition according to claim 1, in which the surface-active agent is a nonionic agent.
Claim 3
Dependent Claim
16 words
A pharmaceutical composition according to claim 2, in which the nonionic agent is polyoxyethylene-hydrogenated castor oil.
References Cited (Backward Citations)
EP0352092A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.